I have an oncology patient, age 27, who was up to date on COVID-19 vaccination but is now in need of hematopoietic cell transplant (HCT). Will she require revaccination after HCT?

Yes. See all information about vaccination of immunocompromised people, including revaccination considerations after HCT and for those on B-cell depleting therapies, at www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#immunocompromised. This is the most current statement from CDC on COVID-19 vaccination after HCT:

Recipients of HCT or CAR-T-cell therapy who received 1 or more doses of COVID-19 vaccine prior to or during treatment should be revaccinated. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy and should follow the currently recommended schedule for immunocompromised people who are unvaccinated.

A patient’s clinical team is best positioned to determine the degree of immune compromise, need for revaccination, and appropriate timing of revaccination.